Abstracts Archive - Page 2309 of 2425 - ACR Meeting Abstracts

Abstract Number: 1716 • 2012 ACR/ARHP Annual Meeting
Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: A number of clinical trials using intensive immunosuppression followed by autologous haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) are underway or have…
Abstract Number: 1677 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children
Matthew L. Stoll¹, Anthony B. Morlandt², Suwat Teerawattanapong², Daniel Young³, Peter D. Waite⁴ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Radiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Temporomandibular joint (TMJ) arthritis occurs in as much as 80% of children with juvenile idiopathic arthritis (JIA) and can result in substantial facial deformity.…
Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Gina Patel³, Vipin Arora⁴, Hartmut Kupper⁵ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, ³Abbott, Abbott Park, IL, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…
Abstract Number: 1679 • 2012 ACR/ARHP Annual Meeting
Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up
D. J. Lovell¹, N. Ruperto², R. Mouy², E. Paz², N. Rubio-Perez², C. A. Silva², C. Abud-Mendoza², R. Burgos-Vargas², V. Gerloni², J. a. Melo-Gomes³, C. Saad-Magalhaes², J. Chavez⁴, C. Huemer², A. Kivitz², F. Blanco², I. Foeldvari², Michael Hofer⁵, H. Huppertz², C. Job Deslandre², K. Minden², A. Flores Nunez⁶, A. J. Block⁷ and A. Martini², ¹Cincinnati Children's Hospital, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ⁴PRINTO, Genoa, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁶PRINTO, IRCCS Hospital para el Niño Poblano, Puebla, Mexico, ⁷Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: We previously reported the efficacy and safety of abatacept (ABA) in patients with juvenile idiopathic arthritis (JIA) in the AWAKEN trial1, during the 4-month…
Abstract Number: 1680 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of the Assessment of Spondyloarthropathy International Society (ASAS) Criteria for Children with Enthesitis Related Arthritis (ERA): A Single Center Study of 124 Patients
Mehul Jariwala¹, Manjari Agarwal¹ and Sujata Sawhney², ¹Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India, ²Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India
Background/Purpose: Enthesitis Related Arthritis (ERA) is a common subtype (36%) of Juvenile Idiopathic Arthritis (JIA) seen in India 1. These criteria do not distinguish between…
Abstract Number: 1681 • 2012 ACR/ARHP Annual Meeting
Increased Arterial Stiffness in Juvenile Idiopathic Arthritis (JIA) Patients Compared with Matched Controls – a Pilot Study
Hanne Aulie¹, Mette-Elise Estensen², Anne Marit Selvaag¹, Patrick Segers³, Oyvind Molberg⁴, Vibke Lilleby¹, Svend Aakhus² and Berit Flatø⁴, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ³IBiTech-bioMMeda, Ghent University, Ghent, Belgium, ⁴Department of Rheumatology, Oslo University hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Systemic arterial properties in adult patients with JIA are not well described. The aim of this study was to evaluate arterial properties in young…
Abstract Number: 1682 • 2012 ACR/ARHP Annual Meeting
Sustained Clinical Remission (Disease Activity Score 28 <2.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Jaap Fransen², Alfons A. den Broeder³, Calin Popa¹ and Piet L.C.M. van Riel¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation appears to be an independent risk factor for CVD in rheumatoid arthritis (RA), but there is no clear difference in CVD risk…
Abstract Number: 1683 • 2012 ACR/ARHP Annual Meeting
Associations Between Lipid and Rheumatoid Arthritis Genetic Factors, and Low Density Lipoprotein Levels in RA Patients
Katherine P. Liao¹, Dorothee Diogo², Tianxi Cai³, Jing Cui⁴, Raul N. Guzman P.⁵, Vivian Gainer⁵, Shawn N. Murphy⁵, Susanne Churchill⁶, Isaac Kohane⁷, Elizabeth W. Karlson¹ and Robert M. Plenge⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Biostatistics, Harvard School of Public Health, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Research Computing, Partners Healthcare Systems, Boston, MA, ⁶Information Systems, Partners Healthcare Systems, Boston, MA, ⁷Medicine, Brigham and Women's Hospital, Boston, MA, ⁸Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Associations between lipid and rheumatoid arthritis genetic factors, and low density lipoprotein levels in RA patientsBackground/Purpose: In epidemiologic studies, low density lipoprotein (LDL), a major…
Abstract Number: 1684 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents
Signe Abitz Winther¹, Peter Riis Hansen¹, Søren Lund Kristensen¹, Lene Dreyer², Ole Ahlehoff¹, Louise Linde³, Christian Torp-Pedersen¹ and Jesper Lindhardsen¹, ¹Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease, but in contrast to the well-established risk of myocardial infarction (MI), the…
Abstract Number: 1685 • 2012 ACR/ARHP Annual Meeting
Differential Impact of Cardiac Risk Factors On Coronary Plaque Presence and Features in Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls
George A. Karpouzas¹, Jennifer Malpeso², Tae-Young Choi², Silvia Munoz¹ and Matthew Budoff², ¹Rheumatology, Harbor-UCLA, Torrance, CA, ²Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Traditional cardiac risk factors (CRFs) associate with myocardial infarction (MI) risk in both Rheumatoid arthritis (RA) and the general population. Subclinical atherogenesis has been…
Abstract Number: 1686 • 2012 ACR/ARHP Annual Meeting
Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients
Ausaf Mohammad¹, Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Vertebral Fracture Assessment-detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients Background/Purpose: Osteoporosis and cardiovascular disease (CVD) are major comorbidities and CVD…
Abstract Number: 1687 • 2012 ACR/ARHP Annual Meeting
The Risk of Atrial Fibrillation in Patients with Rheumatoid Arthritis Compared to the General Population: A Large Cohort Study
Seoyoung C. Kim¹, Jun Liu² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: It is well-known that rheumatoid arthritis (RA) is associated with cardiovascular disease such as myocardial infarction. However, little evidence exists on the risk of…
Abstract Number: 1688 • 2012 ACR/ARHP Annual Meeting
Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis
Hani S. El-Gabalawy¹, David B. Robinson¹, Irene Smolik¹, Donna M. Hart¹, Elizabeth D. Ferucci², Marianna M. Newkirk³, Marvin J. Fritzler⁴, Catriona Cramb⁵, Jeremy Sokolove⁶ and William H. Robinson⁷, ¹Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ²Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁴Medicine, University of Calgary, Calgary, AB, Canada, ⁵CCSR 4135 Immunology Rheumatol, Stanford University, Palo Alto, CA, ⁶Medicine, Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is prevalent, severe, and predominantly seropositive in many North American Native (NAN) populations. We have shown a strong tendency towards familial…
Abstract Number: 1689 • 2012 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies: A Novel Biomarker with Clinical and Mechanistic Implications in Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Herbert Bull³, Felipe Andrade⁴ and Antony Rosen¹, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Consultant, Westfield, NJ, ⁴Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminases (PADs) have emerged as key participants in the pathogenesis of rheumatoid arthritis (RA) due to their expression in inflamed RA synovium and…
Abstract Number: 1690 • 2012 ACR/ARHP Annual Meeting
Citrullination within the Atherosclerotic Plaque: A New Potential Target for Anti-Citrullinated Protein Antibodies
Jeremy Sokolove¹, Orr Share¹, Matthew Brennan¹, Lauren J. Lahey¹, Amy H. Kao², Eswar Krishnan³, Mary Chester M. Wasko⁴ and William H. Robinson⁵, ¹Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ²Lupus Center of Excellence, Allegheny Singer Research Institute, Pittsburgh, PA, ³Medicine, Standford University, Palo Alto, CA, ⁴West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease due to accelerated atherosclerosis. This risk has mainly been limited to seropositive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].